vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Andersons, Inc. is the larger business by last-quarter revenue ($329.5M vs $168.4M, roughly 2.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -2.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ANDE vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $168.4M |
| Net Profit | $67.4M | — |
| Gross Margin | 70.3% | — |
| Operating Margin | 26.6% | 50.6% |
| Net Margin | 20.5% | — |
| Revenue YoY | -2.4% | 143.7% |
| Net Profit YoY | 49.6% | — |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $329.5M | $168.4M | ||
| Q3 25 | $295.8M | $87.3M | ||
| Q2 25 | $535.0M | $82.4M | ||
| Q1 25 | $370.8M | $65.0M | ||
| Q4 24 | $337.5M | $69.1M | ||
| Q3 24 | $231.9M | $51.6M | ||
| Q2 24 | $492.5M | $73.8M | ||
| Q1 24 | $341.4M | $137.7M |
| Q4 25 | $67.4M | — | ||
| Q3 25 | $20.1M | $-31.3M | ||
| Q2 25 | $7.9M | $-12.7M | ||
| Q1 25 | $284.0K | $-40.5M | ||
| Q4 24 | $45.1M | — | ||
| Q3 24 | $27.4M | $-29.5M | ||
| Q2 24 | $36.0M | $-61.9M | ||
| Q1 24 | $5.6M | $61.0M |
| Q4 25 | 70.3% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 29.6% | — | ||
| Q1 25 | 41.2% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | 76.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 37.6% | — |
| Q4 25 | 26.6% | 50.6% | ||
| Q3 25 | 8.7% | -11.4% | ||
| Q2 25 | 4.6% | 8.6% | ||
| Q1 25 | 0.9% | -34.0% | ||
| Q4 24 | 19.9% | -6.4% | ||
| Q3 24 | 26.8% | -31.0% | ||
| Q2 24 | 11.6% | 3.5% | ||
| Q1 24 | 4.1% | 52.5% |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 6.8% | -35.9% | ||
| Q2 25 | 1.5% | -15.4% | ||
| Q1 25 | 0.1% | -62.2% | ||
| Q4 24 | 13.4% | — | ||
| Q3 24 | 11.8% | -57.2% | ||
| Q2 24 | 7.3% | -83.9% | ||
| Q1 24 | 1.6% | 44.3% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | $0.59 | $-0.16 | ||
| Q2 25 | $0.23 | $-0.06 | ||
| Q1 25 | $0.01 | $-0.21 | ||
| Q4 24 | $1.31 | $-0.14 | ||
| Q3 24 | $0.80 | $-0.15 | ||
| Q2 24 | $1.05 | $-0.33 | ||
| Q1 24 | $0.16 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $167.9M |
| Total DebtLower is stronger | $560.0M | — |
| Stockholders' EquityBook value | $1.2B | $-302.0M |
| Total Assets | $3.7B | $465.9M |
| Debt / EquityLower = less leverage | 0.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.3M | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | $561.8M | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $560.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $608.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $-302.0M | ||
| Q3 25 | $1.2B | $-451.4M | ||
| Q2 25 | $1.4B | $-433.5M | ||
| Q1 25 | $1.4B | $-426.2M | ||
| Q4 24 | $1.4B | $-388.7M | ||
| Q3 24 | $1.3B | $-370.2M | ||
| Q2 24 | $1.3B | $-344.2M | ||
| Q1 24 | $1.3B | $-294.3M |
| Q4 25 | $3.7B | $465.9M | ||
| Q3 25 | $3.3B | $364.0M | ||
| Q2 25 | $3.4B | $347.1M | ||
| Q1 25 | $3.8B | $324.0M | ||
| Q4 24 | $4.1B | $343.8M | ||
| Q3 24 | $3.4B | $314.1M | ||
| Q2 24 | $3.3B | $352.3M | ||
| Q1 24 | $3.3B | $373.1M |
| Q4 25 | 0.45× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | $45.2M |
| Free Cash FlowOCF − Capex | $-77.1M | — |
| FCF MarginFCF / Revenue | -23.4% | — |
| Capex IntensityCapex / Revenue | 21.5% | 0.0% |
| Cash ConversionOCF / Net Profit | -0.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | $45.2M | ||
| Q3 25 | $233.9M | $-4.3M | ||
| Q2 25 | $299.3M | $-31.4M | ||
| Q1 25 | $-350.0M | $-22.6M | ||
| Q4 24 | $268.8M | $-35.0M | ||
| Q3 24 | $-2.1M | $-35.3M | ||
| Q2 24 | $304.4M | $-7.2M | ||
| Q1 24 | $-239.6M | $53.8M |
| Q4 25 | $-77.1M | — | ||
| Q3 25 | $167.0M | — | ||
| Q2 25 | $250.5M | — | ||
| Q1 25 | $-396.6M | — | ||
| Q4 24 | $212.9M | — | ||
| Q3 24 | $-40.0M | $-35.5M | ||
| Q2 24 | $275.8M | $-7.3M | ||
| Q1 24 | $-266.4M | $53.8M |
| Q4 25 | -23.4% | — | ||
| Q3 25 | 56.5% | — | ||
| Q2 25 | 46.8% | — | ||
| Q1 25 | -106.9% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | -17.2% | -68.7% | ||
| Q2 24 | 56.0% | -9.9% | ||
| Q1 24 | -78.0% | 39.0% |
| Q4 25 | 21.5% | 0.0% | ||
| Q3 25 | 22.6% | 0.0% | ||
| Q2 25 | 9.1% | 0.0% | ||
| Q1 25 | 12.6% | 0.0% | ||
| Q4 24 | 16.6% | 0.0% | ||
| Q3 24 | 16.3% | 0.3% | ||
| Q2 24 | 5.8% | 0.1% | ||
| Q1 24 | 7.8% | 0.1% |
| Q4 25 | -0.09× | — | ||
| Q3 25 | 11.61× | — | ||
| Q2 25 | 38.10× | — | ||
| Q1 25 | -1232.46× | — | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | — | ||
| Q1 24 | -42.94× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
